Pericarditis
29
7
10
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.4%
1 terminated out of 29 trials
88.9%
+2.3% vs benchmark
21%
6 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (29)
Transition to KPL-387 Monotherapy Dosing & Administration Study
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
RUDRA Registry (Real-World Clinical Registry for Patients With Recurrent Pericarditis)
Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Effects of Pulmonary Rehabilitation Versus Standard Care in Patients With Pericarditis
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
Pericardial Imaging Study
CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome
COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
Post-Ablation Pericarditis Reduction Study (PAPERS)
Inflammatory Cardiomyopathy Bern Registry
Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels
Inflammation in Acute Cardiovascular Diseases - the CArdiovascular Inflammation Registry (CAIR)
ACAM2000® Myopericarditis Registry
MYocarditis and/or Pericarditis Following mRNA COVID-19 VACCination National Surveillance Study
Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in Children
Post-Ablation Pericarditis Reduction Study
Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis